Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18590
Title: Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer.
Authors: Johnstone, Cameron N;Chand, Ashwini;Putoczki, Tracy L;Ernst, Matthias
Affiliation: Cancer & Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;
Cancer Metastasis Laboratory, Cancer Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
School of Cancer Medicine, LaTrobe University, Heidelberg, VIC 3084, Australia
Department of Medical Biology, Melbourne University, Parkville, VIC, Australia
Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Oct-2015
EDate: 2015-07-14
Citation: Cytokine & growth factor reviews 2015; 26(5): 489-98
Abstract: Interleukin (IL)-11 is a member of the IL-6 family of cytokines that is defined by the shared use of the GP130 signal transducing receptor subunit. In addition of its long recognized activities as a hemopoietic growth factor, IL-11 has an emerging role in epithelial cancer biology. Through the activation of the GP130-Janus kinase signaling cascade and associated transcription factor STAT3, IL-11 can confer many of the tumor intrinsic 'hallmark' capabilities to neoplastic cells, if they express the ligand-specific IL-11Rα receptor subunit. Accordingly, IL-11 signaling has recently been identified as a rate-limiting step for the growth tumors arising from the mucosa of the gastrointestinal tract. However, there is less appreciation for a potential role of IL-11 to support breast cancer progression, apart from its well documented capacity to facilitate bone metastasis. Here we review evidence that IL-11 expression in breast cancer correlates with poor disease outcome and discuss some of the molecular mechanisms that are likely to underpin these observations. These include the capacity of IL-11 to stimulate survival and proliferation of cancer cells alongside angiogenesis of the primary tumor and of metastatic progenies at distant organs. We review current strategies to interfere with IL-11 signaling and advocate that inhibition of IL-11 signaling may represent an emerging therapeutic opportunity for numerous cancers.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18590
DOI: 10.1016/j.cytogfr.2015.07.015
ORCID: 0000-0002-6399-1177
PubMed URL: 26209885
Type: Journal Article
Research Support, Non-U.S. Gov't
Review
Subjects: Cancer
IL-11
IL-6
Interleukin
STAT3
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.